Krueger G G, Ellis C N
Department of Dermatology, University of Utah Health Sciences Center, 50 North Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, USA.
Br J Dermatol. 2003 Apr;148(4):784-8. doi: 10.1046/j.1365-2133.2003.05239.x.
Alefacept, human LFA-3/IgG1 fusion protein, is a novel biological agent currently being developed for the treatment of chronic plaque psoriasis. Alefacept selectively reduces the memory-effector T cells that have been implicated in the pathogenesis of the disease; as a result, alefacept is classified as a therapy that induces remission (so-called 'remittive' therapy). In a previously published randomized, placebo-controlled phase II study of intravenous alefacept in 229 patients with chronic plaque psoriasis, clinical improvement was observed during dosing as well as in the postdosing follow-up period.
To assess the remission period following alefacept therapy.
The time before re-treatment was required was measured in patients who were 'clear' or 'almost clear' of disease according to a physician global assessment at the end of the follow-up phase.
In these patients, responses were sustained for a median of 10 months, and for up to 18 months. No patient reported disease rebound after cessation of alefacept.
Alefacept is a biological agent for the treatment of chronic plaque psoriasis that provides disease-free intervals and time off drug therapy.
阿法赛特，即人淋巴细胞功能相关抗原-3/免疫球蛋白G1融合蛋白，是一种目前正在研发用于治疗慢性斑块型银屑病的新型生物制剂。阿法赛特可选择性减少与该疾病发病机制相关的记忆效应T细胞；因此，阿法赛特被归类为一种诱导缓解的疗法（即所谓的“缓解性”疗法）。在之前发表的一项针对229例慢性斑块型银屑病患者的静脉注射阿法赛特的随机、安慰剂对照II期研究中，在给药期间以及给药后的随访期均观察到了临床改善。
评估阿法赛特治疗后的缓解期。
在随访期结束时，根据医生整体评估，对疾病“清除”或“几乎清除”的患者测量再次治疗前所需的时间。
在这些患者中，缓解持续的中位时间为10个月，最长可达18个月。没有患者在停用阿法赛特后报告疾病复发。
阿法赛特是一种用于治疗慢性斑块型银屑病的生物制剂，可提供无病期和停药期。
